Adenoscan: profile and news

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $18.2 million during the fourth quarter and $78.1 million during the twelve months ... - PR Newswire (press release),

'Tentative' FDA nod on Teva drug Feb 13, 2006
On final approval, the injection will be the AP-rated generic equivalent of Astellas Adenoscan Injection, a product used as an supplement to thallium-201 ... - Jerusalem Post,

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006
Royalty revenues, derived primarily from Adenoscan® (adenosine), totaled $18.2 million during the fourth quarter and $78.1 million during the twelve months ... - Yahoo! News (press release)

Teva Announces Tentative Approval of Adenosine Injection Feb 13, 2006
Upon final approval, Teva's Adenosine Injection will be the AP-rated generic equivalent of Astellas Adenoscan(R) Injection, a product indicated as an adjunct ... - Genetic Engineering News,

Williams-Labadie Promotes Jim Grossmann to Senior Vice President ... Jan 13, 2006
During that time, he has directed a wide range of innovative marketing programs to support the growth of Adenoscan® -- the largest brand in the Astellas ... - PharmaLive.com (press release),

King Pharmaceuticals Reports Third-Quarter 2005 Financial Results Nov 9, 2005
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $22.3 million in the third quarter of 2005 compared to $20.3 million during the same ... - PR Newswire (press release),

King Pharmaceuticals Reports Third-Quarter 2005 Financial Results Nov 9, 2005
Royalty revenues, derived primarily from Adenoscan® (adenosine), totaled $22.3 million in the third quarter of 2005 compared to $20.3 million during the same ... - Yahoo! News (press release)

Regadenoson Phase 3 Data Presented as Late-Breaker at American ... Oct 2, 2005
...perfusion imaging (MPI) studies conducted with regadenoson were comparable to the images from MPI studies conducted with Adenoscan® (adenosine injection). ... - Yahoo! News (press release)

King Pharmaceuticals Reports Second-Quarter 2005 Financial Results Sep 9, 2005
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $19.6 million in the second quarter of 2005 compared to $21.1 million during the ... - Investor's Business Daily (subscription)

Regadenoson Meets Primary Endpoint in First Phase 3 Trial Aug 10, 2005
...confidence that myocardial perfusion imaging (MPI) studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan(R). Adenoscan(R ... - PharmaLive.com (press release),

CV Therapeutics' Phase III Strong With Regadenoson Aug 11, 2005
...confidence that MPI work done with the selective A2A adenosine receptor agonist regadenoson were comparable to those conducted with Adenoscan (adenosine), the ... - BioWorld Online (subscription),

CV Therapeutics drug aces Phase III trial Aug 10, 2005
The Palo Alto company (NASDAQ:CVTX) is developing the drug, regadenoson, as an alternative to another drug, Adenoscan, sold by Astellas Pharma Inc., a Japanese ... - San Francisco Business Times,

Data From Regadenoson Phase 3 Study to Be Presented as Late ... Aug 29, 2005
...with 95 percent confidence that myocardial perfusion imaging (MPI) studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan ... - Yahoo News (press release)

Movers & Shakers Aug 11, 2005
US said that a recent study revealed their heart-imaging agent, Regadenoson, was as effective in monitoring blood flow as the current leading agent, Adenoscan. ... - MarketWatch <**results**>

Daiichi Pharmaceutical Co., Ltd.: Launch of Adenoscan Injection ... Jun 20, 2005
...(President: Kiyoshi Morita) and Daiichi Suntory Pharma Co., Ltd. (President: George Nakayama) announced today that Adenoscan. ® Injection ... - PharmaLive.com (press release)

Daiichi Pharmaceutical, Daiichi Suntory Pharma Now Bring Adenoscan ... Jun 22, 2005
2005 (JCNN via COMTEX) -- Tokyo, June 22, 2005 - (JCN) - Daiichi Pharmaceutical (TSE: 4505) announced on June 20 that it has released Adenoscan Injection 60mg ... - Investor's Business Daily (subscription)

The Many Ways to Myocardial Perfusion Imaging Jun 12, 2005
Safety profile of adenosine stress perfusion imaging: results from the Adenoscan multicenter trial registry. J Am Coll Cardiol 1994;23:384-9. 45. ... - RedNova.com,

Astellas And King File Lawsuit Against Adenoscan(R) Generic for ... May 27, 2005
...(collectively, "Sicor") regarding submission of an abbreviated new drug application ("ANDA") for a generic version of Adenoscan(R) (adenosine injection), a ... - mysan.de (Pressemitteilung),

Daiichi Pharmaceutical Co., Ltd.: Notice of Revision of FY2004 ... Apr 21, 2005
...and HANP , an agent for treating acute cardiac insufficiency, and on April 11, 2005, the company obtained importing approval for Adenoscan, an adjunctive agent ... - PharmaLive.com

Yamanouchi and Fujisawa form Astellas Pharma Apr 5, 2005
The company will continue to support its mainstay prescription products including Prograf, VESIcare, Protopic, Adenoscan, AmBisome and Flomax. ... - Pharmaceutical Business Review

Yamanouchi, Fujisawa Unite to Form Astellas Pharma US, Inc., North ... Apr 1, 2005
...and kidney transplants, VESIcare® for the treatment of overactive bladder, Protopic®, for the treatment of atopic dermatitis, Adenoscan® a pharmacologic ... - Yahoo News

Yamanouchi, Fujisawa Unite to Form Astellas Pharma US, Inc., North ... Apr 1, 2005
...after liver and kidney transplants, VESIcare(R) for the treatment of overactive bladder, Protopic(R), for the treatment of atopic dermatitis, Adenoscan(R) a ... - PharmaLive.com,

King Pharmaceuticals Repositioned for Growth Feb 28, 2005
...levothyroxine sodium tablets, USP); dependence of the effect of generic substitution for Levoxyl(R); dependence on royalty revenues from Adenoscan(R) (adenosine ... - PR Newswire (press release)

Other information

Indication
For the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)

Pharmacology
Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.

Mechanism Of Action
Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.

Drug Category
Vasodilator Agents; Antiarrhythmic Agents; Analgesics; Cardiac drugs; ATC:C01EB10

Brand Names/Synonyms
2'-Deoxyadenosine; Adenine Deoxy Nucleoside; Adenine Deoxyribonucleoside; Adenine Deoxyribose; Adenine Nucleoside; Adenine Riboside; Adenocard; Adenocor; Adenoscan; Adenosin; Adenosine; Adenosine 99%; Adenosine for Biochemistry; Adenosine, Free Base; Adensoine; Adenyldeoxyriboside; Boniton; CCRIS 1782; Da; Deoxyadenosine; Desoxyadenosine; Myocol; Nucleocardyl; Sandesin; Usaf Cb-10

Dosage Forms
LIQUID

Absorption
Not Available

Interactions
Interactions for Adenosine:

Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile. Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents. The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.

The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline. In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective. Adenosine effects are potentiated by dipyridamole. Thus, smaller doses of adenosine may be effective in the presence of dipyridamole. Carbamazepine has been reported to increase the degree of heart block produced by other agents. As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.

Chemical IUPAC Name
2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

Chemical Formula
C10H13N5O4

Half Life
<10 secs

Drug Type
Approved Drug

# Accession No
APRD00132

CAS Registry Number
58-61-7